| ²é¿´: 2541 | »Ø¸´: 23 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
286293287½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
Ò©Æ·×¢²áÓÃÓ¢Óï
|
||
|
Ò©Æ·×¢²áÓÃÓ¢Óï ÏÖÔÚ×ö×¢²á×ÊÁϾ³£»áÉæ¼°Ó¢Óï±í´ï£¬ÎªÁËʹÎÒÃÇдע²á×ÊÁÏʱµÄÓ¢Óï¸ü´¿Õý£¬Ï£Íû¸÷λ´ïÈËÄÜ»ý¼«ÓÂÔ¾Ìṩ¾³£Éæ¼°µÄÓ¢Óï±í´ï£¬Ê¹ÎÒÃǵÄ×¢²áˮƽ¸üÉÏÒ»²ãÂ¥¡£ ÎÒÏÈÅ×שÒýÓñ CEP£ºÅ·ÖÞÒ©µäÊÊÓ¦ÐÔÖ¤Êécertificate of suitability to monograph of European Pharmacopoeia¡£ÊÇÅ·ÖÞÒ©µäËùÊÕÔØµÄÔÁÏÒ©µÄÒ»ÖÖÈÏÖ¤³ÌÐò£¬ÓÃÒÔÈ·¶¨ÔÁÏÒ©µÄÖÊÁ¿¿ÉÒÔÓÃÅ·ÖÞÒ©µäµÄ·½·¨¼ÓÒÔ¿ØÖÆ¡£ÕâÒ»³ÌÐòÊÊÓÃÓÚÉú²úµÄºÍÌáÈ¡µÄÓлú»òÎÞ»úÎïÖÊÒÔ¼°·¢½ÍÉú²úµÄ·ÇÖ±½Ó»ùÒò²úÆ·¡£ DMF£ºDrug master FileÃÀ¹úÒ©ÎïÖ÷Îļþµµ°¸¡£ÊÇÖ¸Ìá½»¸øFDAµÄÓÃÓÚÌṩ¹ØÓÚÈËÓÃÒ©Æ·µÄÉú²úÉ豸¡¢¹¤ÒÕ»òÉú²ú¡¢¹¤ÒÕ´¦Àí¡¢°ü×°ºÍ´¢´æÖÐʹÓõÄÎïÁϵÄÏêϸµÄºÍ±£ÃܵÄÐÅÏ¢¡£·ÖΪÎåÖÖÀàÐÍ£º I£º Éú²úµØµã¡¢É豸¡¢²Ù×÷³ÌÐòºÍÈËÔ± II£º ÔÁÏÒ©¡¢ÔÁÏÒ©ÖмäÌå¡¢Éú²úÔÁÏÒ©ºÍÖмäÌåʹÓõÄÎïÁϺÍÒ©Æ· III£º°ü×°²ÄÁÏ IV£º¸³ÐμÁ¡¢É«ËØ¡¢µ÷ζ¼Á¡¢ÏãÁÏ»òÉú²úÕâЩÎïÖÊËùÓõÄÎïÁÏ V£º FDA½ÓÊܵIJο¼ÐÅÏ¢ EDMF£ºEuropean Drug Master FileÅ·ÖÞÒ©ÎïÖ÷Îļþµµ°¸¡£ÊÇָŷÖÞÖÆ¼ÁÉêÇëÖÐÓйØÔÁÏÒ©ÐÅÏ¢µÄÎļþ£¬ÓÖ³ÆÔÁÏÒ©Ö÷Îļþµµ°¸£¨ASMF£©¡£EDMF Ö»ÓÐÔÚÖÆ¼ÁÉêÇëµÄÖ§³ÖϲÅÄÜÌá½»¡£EDMF·ÖΪÁ½²¿·Ö£º 1£® ÉêÇëÈ˲¿·Ö£¨AP£©£º¹©ÖƼÁÉêÇëÈËʹÓõķDZ£ÃÜÐÅÏ¢£» 2. ÏÞÖÆ²¿·Ö£¨RP£©£ºEDMF³ÖÓÐÈËÈÏΪÊDZ£ÃܵÄÐÅÏ¢¡£ EDMFµÄʹÓ÷¶Î§£º 1. ÐÂÔÁÏÒ© 2. ÒÑÖªµÄµ«Å·ÖÞÒ©µä»òÆä³ÉÔ±¹úÒ©µäûÓÐÊÕÔØµÄÔÁÏÒ© 3. Å·ÖÞÒ©µä»ò³ÉÔ±¹úÒ©µäÒÑÊÕÔØµÄÔÁÏÒ© ANDA£ºAbbreviated New Drug Application ÃÀ¹ú¼òÂÔÐÂÒ©ÉêÇë¡£ÊÇFDA¹æ¶¨µÄ·ÂÖÆÒ©ÉêÇë³ÌÐò¡£ Generic£º·ÂÖÆµÄ£¬·ÇÌØÊâµÄ API£ºActive Pharmaceutical Ingredient ÔÁÏÒ© Dossier£ºÎĵµ£¬µµ°¸¡£ TSE£ºTransmitting animal Spongiform Encephalopathy agent ´«²¥ÐÔ¶¯ÎﺣÃà×´ÄÔ²¡Ìå Q7A£ºICH£¨¹ú¼Êе÷»áÒ飩 ÔÁÏÒ©GMP Ö¸ÄÏ¡£²ûÊöÁËÔÁÏÒ©Éú²úÉÌÓ¦×ñѵÄGMPÖ¸µ¼ÔÔò¡£ Start Material£º¼ò³ÆSM£¬ÆðʼÎïÁÏ¡£ÆðʼÎïÁÏͨ³£±êÖ¾×ÅÉú²ú¹ý³ÌµÄ¿ªÊ¼¡£ºÏ³É¹¤ÒÕÔÁÏÒ©µÄÆðʼÎïÁÏÊÇÖ¸¹¹³ÉÔÁÏÒ©Ö÷Òª½á¹¹Æ¬¶ÏµÄÒ»ÖÖÔ²ÄÁÏ¡¢ÖмäÌå»òÕßÔÁÏÒ©£»Ëü¿ÉÒÔÊÇÒ»ÖÖÉÌÆ·£¬Ò²¿ÉÒÔÊÇÄÚ²¿Éú²úµÄÎïÖÊ£»ÆðʼÎïÁÏÒ»°ã¾ßÓÐÃ÷È·µÄÐÔÖʺͽṹ¡£ BPR£ºBritish Pharmacopoeia Reference Ó¢¹úÒ©µä¶ÔÕÕÆ· EPR£ºEuropean Pharmacopoeia Reference Å·ÖÞÒ©µä¶ÔÕÕÆ· COA£ºCertificate Of Analysis ·ÖÎö±¨¸æµ¥ Food Additive£ºÊ³Æ·Ìí¼Ó¼Á¡£FDA ¶ÔʳƷÌí¼Ó¼ÁµÄ¶¨ÒåÊÇÖ¸ÈκÎÒ»ÖÖÎïÖÊ£¬ËüµÄÔ¤ÆÚµÄÓÃ;¿ÉÒÔ»ò±»ÆÚÍû¿ÉÒÔÖ±½Ó»ò¼ä½ÓµØÊ¹ÕâÖÖÎïÖʳÉΪijһʳƷÖеijɷֻòÓ°ÏìʳƷµÄÌØÕ÷¡£GRASÎïÖʼ°ÎÞÉøÒÆ»ò¼«ÉÙÉøÒÆµÄʳƷ½Ó´¥ÐÔÎïÖʳýÍâ¡£ Dietary Supplement£º Òûʳ²¹³ä¼Á¡£ÃÀ¹ú£±£¹£¹£´Äê°ä²¼µÄ¡¶Òûʳ²¹³ä¼Á½¡¿µÓë½ÌÓý·¨¡·£¨£Ä£Ó£È£Å£Á£©ÖУ¬È·Á¢ÁËÒûʳ²¹³ä¼ÁµÄ¶¨Òå¡£Òûʳ²¹³ä¼ÁÊÇÖ¸º¬ÓС°Òûʳ³É·Ö¡±µÄ¿Ú·þ²úÆ·¡£Õâ Щ²úÆ·ÖÐËùº¬Óеġ°Òûʳ³É·Ö¡±°üÀ¨£ºÎ¬ÉúËØ¡¢¿óÉúÎï¡¢²Ý±¾»òÆäËûÖ²Îï¡¢°±»ùËᣬÒÔ¼°Ã¸¡¢Æ÷¹Ù×éÖ¯¡¢ÏÙÌåºÍ´úлÎïÖ®ÀàµÄÎïÖÊ¡£Òûʳ²¹³ä¼ÁÒ²¿ÉÒÔÊÇÝÍÈ¡Îï»òŨ ËõÎ¶øÇÒ¿ÉÒÔÖÆ³ÉƬ¼Á¡¢½ºÄÒ¡¢Èí½ºµÈ¶àÖÖÐÎʽ¡£ [ Last edited by shich68 on 2008-5-6 at 09:37 ] |
» ²ÂÄãϲ»¶
¶þÌǵÄÌÇÖ¬£¬ºÏ³Éºósephadex LH-20·ÖÀë²»³öÀ´£¬ÇóÖú
ÒѾÓÐ1È˻ظ´
ÄÏ·½Ò½¿Æ´óѧÖé½Ò½ÔºÐ¤¼ÆÉú¿ÎÌâ×éÕÐÊÕ²©Ê¿Éú £¨2026ÄêÈëѧ£©
ÒѾÓÐ2È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ190È˻ظ´
349ҩѧר˶105500Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
298Çóµ÷¼ÁÒ»Ö¾Ô¸Öк£Ñó
ÒѾÓÐ3È˻ظ´
ҩѧµ÷¼ÁÉêÇë×Ô¼öÐÅ£¬Ò»Ö¾Ô¸ÖÐÄÏ´óѧ
ÒѾÓÐ1È˻ظ´
ҩѧ349ר˶Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¡¶×óÒÒÀÎ÷̹עÉäÒºÖÆ±¸¹¤ÒÕÑо¿¡¢ÖÊÁ¿¿ØÖƺÍÎȶ¨ÐÔÑо¿¡·ÏÂÔØ
ÒѾÓÐ1È˻ظ´
105500ҩѧÇóµ÷¼Á£¬Ò»Ö¾Ô¸É½¶«´óѧҩѧ£¬348·Ö
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
harrisonzhang
ľ³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3159
- Ìû×Ó: 19
- ÔÚÏß: 62.4Сʱ
- ³æºÅ: 353454
- ×¢²á: 2007-04-23
- ÐÔ±ð: GG
- רҵ: Éñ¾ÉúÎïѧ

2Â¥2007-12-12 02:50:11
286293287
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 988.3
- Ìû×Ó: 197
- ÔÚÏß: 17.4Сʱ
- ³æºÅ: 461045
- ×¢²á: 2007-11-18
- ÐÔ±ð: MM
- רҵ: »¯Ñ§
3Â¥2007-12-12 09:54:15
qingerzheng
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 213
- ºì»¨: 1
- Ìû×Ó: 120
- ÔÚÏß: 60.3Сʱ
- ³æºÅ: 288275
- ×¢²á: 2006-10-21
- רҵ: Ò©¼Á
4Â¥2008-01-03 14:09:45
À¶Ìì°×ÔÆ263
Òø³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 446
- Ìû×Ó: 40
- ÔÚÏß:
- ³æºÅ: 507501
- ×¢²á: 2008-02-19
- ÐÔ±ð: MM
- רҵ: ¶¯Îïҩѧ
5Â¥2008-03-01 09:46:26
°®¿´ÐÇÐǵÄÓã
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 455.7
- Ìû×Ó: 102
- ÔÚÏß:
- ³æºÅ: 149969
- ×¢²á: 2005-12-29
- ÐÔ±ð: MM
- רҵ: ÉúÎïÒ½ÓòÄÁÏ
6Â¥2008-03-04 11:28:48
hxwhu
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 1506.8
- Ìû×Ó: 222
- ÔÚÏß: 9.5Сʱ
- ³æºÅ: 358286
- ×¢²á: 2007-04-28
- ÐÔ±ð: GG
- רҵ: ÉúÎï´ó·Ö×ӽṹÓ빦ÄÜ
|
²¹ÉÏ£º FDAÓйØÊõÓï ·¢²¼Ê±¼ä£º2005-04-13 FDA£¨food and drug administration£©£º £¨ÃÀ¹ú£©Ê³Æ·Ò©Æ·¹ÜÀí¾Ö IND£¨investigational new drug£©£º ÁÙ´²Ñо¿ÉêÇ루ָÉ걨½×¶Î,Ïà¶ÔÓÚNDA¶øÑÔ£©£» Ñо¿ÖеÄÐÂÒ©£¨Ö¸ÐÂÒ©¿ª·¢½×¶Î£¬Ïà¶ÔÓÚÐÂÒ©¶øÑÔ£¬¼´ÁÙ´²Ç°Ñо¿½áÊø£© NDA£¨new drug application£©£ºÐÂÒ©ÉêÇë ANDA£¨abbreviated new drug application£©£º¼ò»¯ÐÂÒ©ÉêÇë epËߣ¨export application£©£º ³ö¿ÚÒ©ÉêÇ루ÉêÇë³ö¿Ú²»±»Åú×¼ÔÚÃÀ¹úÏúÊÛµÄÒ©Æ·£© treatment IND£ºÑо¿ÖеÄÐÂÒ©ÓÃÓÚÖÎÁÆ abbreviated£¨new£©drug£º¼ò»¯ÉêÇëµÄÐÂÒ© DMF£¨drug master file£©£º Ò©ÎïÖ÷Îļþ£¨³ÖÓÐÕßΪ½÷É÷Æð¼û¶ø×¼±¸µÄ±£ÃÜ×ÊÁÏ£¬¿ÉÒÔ°üÀ¨Ò»¸ö»ò¶à¸öÈËÓÃÒ©ÎïÔÚÖÆ±¸¡¢¼Ó¹¤¡¢°ü×°ºÍÖü´æ¹ý³ÌÖÐËùÉæ¼°µÄÉ豸¡¢Éú²ú¹ý³Ì»òÎïÆ·¡£Ö»ÓÐÔÚdmf³ÖÓÐÕß»òÊÚȨ´ú±íÒÔÊÚȨÊéµÄÐÎʽÊÚȨ¸øfda£¬fdaÔÚÉó²éind¡¢nda¡¢andaʱ²ÅÄܲο¼ÆäÄÚÈÝ£© holder£ºDMF³ÖÓÐÕß CFR£¨code of federal regulation£©£º£¨ÃÀ¹ú£©Áª°î·¨¹æ panel£º×¨¼ÒС×é batch production£ºÅúÁ¿Éú²ú£»·ÖÅúÉú²ú batch production records£ºÉú²úÅúºÅ¼Ç¼ post-or pre- market surveillance£ºÏúÊÛǰ»òÏúÊÛºó¼à¶½ informed consent£º ÖªÇéͬÒ⣨»¼Õß¶ÔÖÎÁÆ»òÊÜÊÔÕß¶ÔÒ½ÁÆÊÔÑéÁ˽âºó±íʾͬÒâ½ÓÊÜÖÎÁÆ»òÊÔÑ飩 prescription drug£º´¦·½Ò© OTC drug£¨over¡ªthe¡ªcounter drug£©£º·Ç´¦·½Ò© U£®S£®public health service£ºÃÀ¹úÎÀÉú¸£Àû²¿ NIH£¨national institute of health£©£º£¨ÃÀ¹ú£©È«¹úÎÀÉúÑо¿Ëù clinical trial£ºÁÙ´²ÊÔÑé animal trial£º¶¯ÎïÊÔÑé accelerated approval£º¼ÓËÙÅú×¼ standard drug£º±ê×¼Ò©Îï investigator£ºÑо¿ÈËÔ±£»µ÷ÑÐÈËÔ± preparing and submitting£ºÆð²ÝºÍÉ걨 submission£ºÉ걨£»µÝ½» benifit£¨s£©£ºÊÜÒæ risk£¨s£©£ºÊܺ¦ drug product£ºÒ©Îï²úÆ· drug substance£ºÔÁÏÒ© established name£ºÈ·¶¨µÄÃû³Æ generic name£º·ÇרÀûÃû³Æ proprietary name£º×¨ÓÐÃû³Æ£» INN£¨international nonproprietary name£©£º¹ú¼Ê·ÇרÓÐÃû³Æ narrative summary¼ÇÐðÌå¸ÅÒª adverse effect£º¸±×÷Óà adverse reaction£º²»Á¼·´Ó¦ protocol£º·½°¸ archival copy£º´æµµÓø±±¾ review copy£ºÉó²éÓø±±¾ official compendium£º·¨¶¨Ò©µä£¨Ö÷ÒªÖ¸usp¡¢nf£© USP£¨the united states pharmacopeia£©£ºÃÀ¹úÒ©µä£¨ÏÖÒѺÍnfºÏ²¢Ò»Æð³ö°æ£© NF£¨national formulary£©£º£¨ÃÀ¹ú£©¹ú¼ÒÒ©Æ·¼¯ official£½pharmacopeial= compendial£ºÒ©µäµÄ£»·¨¶¨µÄ£»¹Ù·½µÄ agency£ºÉóÀí²¿ÃÅ£¨Ö¸fda£© sponsor£ºÖ÷°ìÕߣ¨Ö¸¸ºÔð²¢×ÅÊÖÁÙ´²Ñо¿Õߣ© identity£ºÕæÎ±£»¼ø±ð£»ÌØÐÔ strength£º¹æ¸ñ£»¹æ¸ñº¬Á¿£¨Ã¿Ò»¼ÁÁ¿µ¥Î»Ëùº¬ÓÐЧ³É·ÖµÄÁ¿£© labeled amount£º±êʾÁ¿ regulatory specification£ºÖÊÁ¿¹ÜÀí¹æ¸ñ±ê×¼£¨ndaÌṩ£© regulatory methodology£º ÖÊÁ¿¹ÜÀí·½·¨£¨fdaÓÃÓÚ¿¼ºËÔÁÏÒ©»òÒ©Îï²úÆ·ÊÇ·ñ·ûºÏÅú×¼Á˵ÄÖÊÁ¿¹ÜÀí¹æ¸ñ±ê×¼µÄÕûÌײ½Ö裩 regulatory methods validation£º ¹ÜÀíÓ÷ÖÎö·½·¨µÄÑéÖ¤£¨fda¶ÔndaÌṩµÄ·½·¨½øÐÐÑéÖ¤£© dietary supplement£ºÊ³Óò¹³äÆ· |
7Â¥2008-03-04 11:33:00
robbiekean
ľ³æ (ÕýʽдÊÖ)
- DRDEPI: 1
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 2909.1
- É¢½ð: 34
- ºì»¨: 2
- Ìû×Ó: 423
- ÔÚÏß: 66.9Сʱ
- ³æºÅ: 204681
- ×¢²á: 2006-03-02
- ÐÔ±ð: GG
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
8Â¥2008-03-11 08:07:28
9Â¥2008-03-11 23:23:59
10Â¥2008-03-11 23:25:09














»Ø¸´´ËÂ¥








ллÁË£¡²»´í£¡